Trial Profile
A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Jan 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Zilovertamab (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CIRLL
- Sponsors Oncternal Therapeutics, Inc.
- 13 Dec 2022 Results (n=95), presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 10 Dec 2022 According to an Oncternal Therapeutics media release, interim results presented at the American Society of Hematology (ASH) 2022 Annual Meeting.
- 10 Dec 2022 Interim results (n=33) presented in an Oncternal Therapeutics Media Release.